ClinicalTrials.gg
CompletedNCT01427296Updated Jan 18, 2018Results posted

Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing

A Phase 4 interventional study of Polyethylene glycol and Oral sodium phosphate solution in Colon Cleansing, sponsored by Bausch Health Americas, Inc.. Completed at 18 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-01-18.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,154
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to compare the safety and efficacy of OsmoPrep tablets versus HalfLytely and Bisacodyl Tablet Bowel Prep Kit in subjects who are undergoing colonoscopy.

02

Conditions studied

  • Colon Cleansing

Keywords

  • Colon Cleansing
  • Bowel Prep
  • Colonoscopy
03

In context

Lead sponsor

Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.

First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 18 and 70 years of age, inclusive
  • Scheduled for colonoscopy within 21 days of the screening visit
  • Able to swallow tablets the size of a multivitamin without difficulty

Exclusion criteria

Exclusion Criteria:

  • History of -proven acute phosphate nephropathy
  • Known allergy or to treatment arms
  • History of gastric stapling or bypass procedure or history of gastric retention
  • History of any other sodium phosphate preparation within 6 months prior to colonoscopy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,154 participants (actual)

Study arms

  • Active comparator
    OsmoPrep Tablets

    Drug: Oral sodium phosphate solution

  • Active comparator
    HalfLytely and Bisacodyl Tablet

    Drug: Polyethylene glycol

Interventions

  • HalfLytely and Bisacodyl Tablet Bowel Prep Kit, administered as 1 bisacodyl tablet followed by HalfLytely oral solution in a total liquid volume of approximately 2 L

  • OsmoPrep tablets (48 g), administered as 32 total tablets in a total liquid volume of approximately 2 L

06

What researchers measure

Primary outcomes

  1. Distribution of the Overall Colon-cleansing Scale in Each Treatment Group.

    Time frame: 6 months

07

Results

Posted Jan 18, 2018

Participant flow

Participant flow — Overall Study
MilestoneOsmoPrep TabletsHalfLytely and Bisacodyl Tablet
Started10411051
Completed10411051
Not completed00

Outcome measures

PrimaryDistribution of the Overall Colon-cleansing Scale in Each Treatment Group.
Time frame:
6 months
Reported as:
Count of participants · Participants
Distribution of the Overall Colon-cleansing Scale in Each Treatment Group.
ParticipantsOsmoPrep TabletsHalfLytely and Bisacodyl Tablet
Excellent618243
Good275423
Fair116286
Inadequate2388

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OsmoPrep Tablets—20/1,041 (1.9%)443/1,041 (42.6%)
HalfLytely and Bisacodyl Tablet—19/1,051 (1.8%)352/1,051 (33.5%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventOsmoPrep TabletsHalfLytely and Bisacodyl Tablet
Renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/10410/1051
Atrial fibrillationCardiac disorders1/10412/1051
ANAEMIABlood and lymphatic system disorders1/10410/1051
Angina unstableCardiac disorders1/10410/1051
Coronary artery diseaseCardiac disorders1/10410/1051
GoitreEndocrine disorders1/10410/1051
Colitis ischaemicGastrointestinal disorders1/10410/1051
Colitis ulcerativeGastrointestinal disorders1/10410/1051
Colonic FistulaGastrointestinal disorders1/10410/1051
IleusGastrointestinal disorders1/10410/1051
Most frequent other events
Showing 10 of 19
Most frequent other events
EventOsmoPrep TabletsHalfLytely and Bisacodyl Tablet
HyperphosphataemiaMetabolism and nutrition disorders136/10410/1051
NauseaGastrointestinal disorders42/104150/1051
VomitingGastrointestinal disorders23/104145/1051
Urinary tract infectionInfections and infestations34/104138/1051
HypokalaemiaMetabolism and nutrition disorders33/104111/1051
Upper respiratory tract infectionInfections and infestations24/104125/1051
GastritisGastrointestinal disorders21/104111/1051
Abdominal painGastrointestinal disorders12/104121/1051
Back painMusculoskeletal and connective tissue disorders13/104121/1051
HeadacheNervous system disorders20/104116/1051

Baseline characteristics

Age, Customized
Age, Customized(Participants)OsmoPrep TabletsHalfLytely and Bisacodyl TabletTotal
<659069321838
>=65135119254
Sex: Female, Male
Sex: Female, Male(Participants)OsmoPrep TabletsHalfLytely and Bisacodyl TabletTotal
Female6166451261
Male425406831
08

Study locations

18 sites
  • San Carlos, California, United States
  • Bristol, Connecticut, United States
  • Macon, Georgia, United States
  • Suwanee, Georgia, United States
  • Hagerstown, Maryland, United States
  • Wyoming, Michigan, United States
  • Mexico, Missouri, United States
  • Vineland, New Jersey, United States
  • Great Neck, New York, United States
  • New York, New York, United States
  • Fayetteville, North Carolina, United States
  • High Point, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Mentor, Ohio, United States
  • Plano, Texas, United States
  • Chesapeake, Virginia, United States
  • Bellevue, Washington, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2011 to primary completion in Mar 2014, 29 months.

Results were first posted in Jan 2018, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2011
First posted
Sep 1, 2011
StartActual
Sep 16, 2011
Primary completionActual
Mar 11, 2014
CompletionActual
Dec 9, 2014
Results first posted
Jan 18, 2018
Last update
Jan 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01427296
Responsible party
Sponsor
First posted
Sep 1, 2011
Start date
Sep 16, 2011
Primary completion
Mar 11, 2014
Completion
Dec 9, 2014
Results posted
Jan 18, 2018
Last update
Jan 18, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Polyethylene Glycols · Sodium phosphate

Start the discussion